Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oracle
ORCL
|
+$881M |
| 2 |
DoorDash
DASH
|
+$403M |
| 3 |
Amgen
AMGN
|
+$403M |
| 4 |
Amazon
AMZN
|
+$282M |
| 5 |
Applied Materials
AMAT
|
+$231M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$592M |
| 2 |
Workday
WDAY
|
+$580M |
| 3 |
United Parcel Service
UPS
|
+$468M |
| 4 |
Apple
AAPL
|
+$438M |
| 5 |
Atlassian
TEAM
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.97% |
| 2 | Healthcare | 19.05% |
| 3 | Consumer Discretionary | 10.13% |
| 4 | Financials | 9.7% |
| 5 | Industrials | 9.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALPN
576
DELISTED
Alpine Immune Sciences Inc
ALPN
| $17.8M | 0.01% |
450,827
-132,412
| -23% | -$3.91M |
|
577
Evertec
EVTC
$1.97B
| $17.8M | 0.01% |
445,748
-159,061
| -26% | -$6.27M |
|
578
Chubb
CB
$140B
| $17.6M | 0.01% |
67,937
-2,779
| -4% | -$683K |
|
579
Pacira BioSciences
PCRX
$1.04B
| $17.6M | 0.01% |
602,060
-1,973
| -0.3% | -$60.6K |
|
580
PepGen
PEPG
$118M
| $17.2M | 0.01% |
1,166,642
+178,438
| +18% | +$2.11M |
|
581
Camtek
CAMT
$5.92B
| $17.2M | 0.01% |
205,405
-2,445
| -1% | -$192K |
|
582
Carrier Global
CARR
$49.4B
| $17.1M | 0.01% |
294,437
+65,796
| +29% | +$3.7M |
|
583
enGene Therapeutics
ENGN
$120M
| $17.1M | 0.01% |
+1,000,000
| New | +$12.2M |
|
|
MREO
584
Mereo BioPharma
MREO
$48.9M
| $16.9M | 0.01% |
+5,120,573
| New | +$17.3M |
|
585
Vishay Intertechnology
VSH
$4.6B
| $16.9M | 0.01% |
747,269
+261,175
| +54% | +$5.81M |
|
586
Nutrien
NTR
$33.9B
| $16.9M | 0.01% |
310,951
-49,143
| -14% | -$2.56M |
|
587
Simmons First National
SFNC
$3.39B
| $16.8M | 0.01% |
864,630
-476,178
| -36% | -$9.02M |
|
588
Immunocore
IMCR
$1.7B
| $16.7M | 0.01% |
257,080
+80,748
| +46% | +$5.54M |
|
589
Westlake Corp
WLK
$9.26B
| $16.7M | 0.01% |
109,204
-63,235
| -37% | -$8.9M |
|
590
Aon
AON
$80.6B
| $16.7M | 0.01% |
49,947
-359,071
| -88% | -$111M |
|
591
Medpace
MEDP
$16.3B
| $16.6M | 0.01% |
41,124
-2,810
| -6% | -$988K |
|
|
PXD
592
DELISTED
Pioneer Natural Resource Co.
PXD
| $16.6M | 0.01% |
63,312
-160,292
| -72% | -$37.6M |
|
593
General Motors
GM
$80.9B
| $16.5M | 0.01% |
364,334
-10,992
| -3% | -$426K |
|
594
Citigroup
C
$213B
| $16.5M | 0.01% |
260,837
-9,576
| -4% | -$533K |
|
595
First Interstate BancSystem
FIBK
$3.67B
| $16.2M | 0.01% |
596,273
-723,444
| -55% | -$19.8M |
|
596
Weyerhaeuser
WY
$17.6B
| $16.2M | 0.01% |
451,478
+20,425
| +5% | +$691K |
|
597
Pfizer
PFE
$143B
| $16M | 0.01% |
576,175
-204,315
| -26% | -$5.67M |
|
598
California Resources
CRC
$4.49B
| $15.8M | 0.01% |
287,468
+6,312
| +2% | +$330K |
|
|
CHCT
599
Community Healthcare Trust
CHCT
$536M
| $15.7M | 0.01% |
590,442
+580,199
| +5,664% | +$15.3M |
|
600
AerSale
ASLE
$291M
| $15.6M | 0.01% |
2,167,215
+377,397
| +21% | +$3.48M |
|
Similar funds
Janus Henderson Group's Q1 2024 Portfolio in Review
As of Q1 2024, Janus Henderson Group held 2,613 positions worth $183B, up 9.3% from $168B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Janus Henderson Group's Q1 2024 filing shows 67 new, 1,353 increased, 903 reduced and 85 closed positions. Its largest new stake was CG Oncology: 1,521,432 shares worth $66.8M. The largest sale was Abbott, an estimated $592M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q1 2024 buy was CG Oncology: 1,521,432 shares worth $66.8M.
- Janus Henderson Group added most to Oracle in Q1 2024, an estimated $881M increase.
- Janus Henderson Group's biggest Q1 2024 reduction was Abbott, cutting an estimated $592M.
- Janus Henderson Group fully exited Immunogen Inc in Q1 2024, selling an estimated $327M.
- Janus Henderson Group's ten largest holdings make up 28% of its $183B portfolio in Q1 2024.
- Janus Henderson Group opened 67 new positions and closed 85 in Q1 2024.
- Janus Henderson Group's portfolio value rose 9.3% quarter-over-quarter to $183B.
Based on Janus Henderson Group's 13F filing for Q1 2024, filed 15 May 2024.